Transcatheter Edge-to-Edge Repair (TEER) for Mitral Valve Regurgitation

CMS covers mitral valve TEER under Coverage with Evidence Development for symptomatic moderate-to-severe or severe functional MR unresponsive to maximally tolerated GDMT (and CRT if appropriate) and for symptomatic degenerative MR when consistent with FDA-approved indications. Coverage requires use of an FDA-PMA TEER device, documented multidisciplinary heart team care with specified provider qualifications, performance in hospitals meeting infrastructure and volume thresholds, and participation in an approved registry or qualifying clinical study that tracks defined outcomes with at least one year of follow-up.

"TEER is covered for symptomatic moderate-to-severe or severe functional mitral regurgitation (MR) in patients who remain symptomatic despite stable, maximally tolerated guideline-directed medical t..."

Sign up to see full coverage criteria, indications, and limitations.